Insider Transactions in Q1 2024 at Deciphera Pharmaceuticals, Inc. (DCPH)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 16
2024
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,267
-3.95%
|
$34,005
$15.62 P/Share
|
|
Feb 16
2024
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,267
-3.22%
|
$34,005
$15.62 P/Share
|
|
Feb 16
2024
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,010
-3.61%
|
$45,150
$15.62 P/Share
|
|
Feb 16
2024
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,615
-2.35%
|
$39,225
$15.62 P/Share
|
|
Feb 15
2024
|
Daniel C. Martin Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,725
+14.49%
|
-
|
|
Feb 15
2024
|
Dashyant Dhanak EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,275
+9.85%
|
-
|
|
Feb 15
2024
|
Jama Pitman SVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,725
+13.17%
|
-
|
|
Feb 15
2024
|
Thomas Patrick Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,275
+17.17%
|
-
|
|
Feb 15
2024
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,275
+13.43%
|
-
|
|
Feb 07
2024
|
Brightstar Associates LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
914,001
+3.81%
|
$0
$0.01 P/Share
|
|
Jan 16
2024
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,624
-3.3%
|
$22,736
$14.47 P/Share
|
|
Jan 16
2024
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,435
-3.55%
|
$34,090
$14.47 P/Share
|
|
Jan 16
2024
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,624
-3.11%
|
$22,736
$14.47 P/Share
|
|
Jan 16
2024
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,435
-2.52%
|
$34,090
$14.47 P/Share
|